Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
Partnering with the IOF, the University of Oxford and Amgen we have a goal to help reduce global hip & vertebral fractures by 25% by 2025. So, on WOD 2020 we’re proud to share some of the progress made to date. https://t.co/nISWY54WuM
— UCB News (@ucb_news) 20.10.2020 -
On World Osteoporosis Day we are delighted to be part of the Capture the Fracture partnership alongside @IOFbonehealth, @Amgen, and @NDORMS. Watch this short clip to hear a little more about what we are doing. https://t.co/dR2dBsbVqC
— UCB News (@ucb_news) 20.10.2020 -
It is a pleasure to be working with Professor Roland Baron, as part of this year’s virtual #ECTS2020 congress! Professor Baron will be discussing the burden of #osteoporosis and the need to improve #fragilityfracture care - listen to this short clip to f
— UCB News (@ucb_news) 20.10.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
